glp 1 and 2 Current Insights, Advantages Challenges of Small Molecule Glucagon-like Peptide Receptor Agonists: A Scoping Review Part 1 of a 3-Part

Structure and dynamics of the CGRP receptor in apo and peptide-bound forms

A comprehensive review of clinical trials from 2021 highlights that once-weekly subcutaneous semaglutide (1 mg) consistently lowered HbAc by 1.5 to 1.8% over 30 to 56 weeks, outperforming other medications including sitagliptin, dulaglutide, and insulin glargine in the SUSTAIN series.33 Real-world data from 2023 further support these findings, showing an average HbA1c reduction of approximately 0.9% and a fasting blood glucose decrease of 26 mg/dL after six months of once-weekly semaglutide use.34 These results underscore semaglutides ability to offer meaningful improvements in glycemic control and metabolic health for patients with T2DM

In the U.S., this can be done through the FDAs MedWatch program

It has been demonstrated that oxidative stress and excessive generation of ROS affect mitochondrial morphology 30